REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health...

Related Keywords

Hawaii ,United States ,New Mexico ,Japan ,Hawaiian ,Chris Brinzey ,Steve Pakola ,Dana Cormack ,Retina Research ,Wills Eye Retina Service ,Eye Associates Of New Mexico ,Exchange Commission ,Technology Platform Licensees ,Securities Exchange ,Clearside Biomedical Inc ,Nasdaq ,Corporate Communications ,Technology Platform ,Hawaiian Eye ,John Pitcher ,Eye Associates ,Chief Medical Officer ,Clearside Biomedical ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Regenxbio Inc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,